Silo Wellness - CEO, Douglas Gordon
CEO, Douglas Gordon
Source: LinkedIn
  • Silo Wellness (SILO) CEO, Douglas K. Gordon, has been appointed as a director of the company
  • Mr. Gordon has led the company since 2020, through its pre-listing fundraising and entry into the public markets in March 2021
  • His contributions to the company have included developing and launching Silo’s Marley One line of mushroom products in collaboration with the Bob Marley estate
  • Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities
  • Silo Wellness Inc. (SILO) opened trading at $0.035 per share

Silo Wellness (SILO) CEO, Douglas K. Gordon, has been appointed as a director of the company.

Mr. Gordon has led the company since 2020, through its pre-listing fundraising and entry into the public markets in March 2021.

He is the founder of CanEx Jamaica, the premier cannabis business conference and expo in the Caribbean, and has over 30 years of experience spanning finance, media, sales, and marketing.

Mr. Gordon was the visionary behind the launch of Silo’s Marley One line of mushroom products in collaboration with the Bob Marley estate.

The initial Marley One product offering was launched on the e-commerce store and included a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica.

During his career, Mr. Gordon has forged a vast global network and has developed government and distribution relations in Jamaica as an experienced operator of a health and wellness distribution business and psychedelic retreats.

In addition to Mr. Gordon’s appointment to the board, Silo has announced that Mo Yang has resigned from the board of directors to pursue other opportunities.

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities.

Founded in 2018 and headquartered in Toronto, Silo Wellness has operations in Jamaica and Oregon.

Silo Wellness Inc. (SILO) opened trading at $0.035 per share.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.